載入中
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
前收盤價
US$2.14
−US$0.07 · -3.17%
盤中時間採用ET。市場資料可能有所延遲。
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
日內區間
目前US$2.14
52週區間
目前US$2.14
盤中時間採用ET。市場資料可能有所延遲。
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
日內區間
目前US$2.14
52週區間
目前US$2.14
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | 117.6萬 USD | 184萬 USD | 125.7萬 USD |
| 銷貨成本 | — | 35.2萬 USD | 88.9萬 USD | 154.1萬 USD | 130.3萬 USD |
| 毛利 | — | −35.2萬 USD | 28.7萬 USD | 29.9萬 USD | −4.6萬 USD |
| 研究與開發 | 313.1萬 USD | 131.3萬 USD | 165.5萬 USD | 173萬 USD | 87萬 USD |
| 銷售、一般及管理費用 | 476.7萬 USD | 275.4萬 USD | 687.7萬 USD | 866.7萬 USD | 471.7萬 USD |
| 營業費用 | 789.8萬 USD | 406.4萬 USD | 853.2萬 USD | 1039.7萬 USD | 558.7萬 USD |
| 利息收入 | 2.3萬 USD | 6000 USD | 1000 USD | 2000 USD | — |
| 利息支出 | 14.6萬 USD | — | — | — | 182.3萬 USD |
| 折舊和攤銷 | 5000 USD | 35.2萬 USD | 18.2萬 USD | 17.4萬 USD | 2.4萬 USD |
| 營業利益 | −789.8萬 USD | −441.6萬 USD | −824.5萬 USD | −1009.8萬 USD | −563.3萬 USD |
| 淨利 | −887.8萬 USD | −565.5萬 USD | −824.4萬 USD | −1009.6萬 USD | −849.4萬 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
